CLRB

0.85003.73%
DJ

Douglas J. Swirsky

Independent Chairman of the Board

Mr. Douglas J. Swirsky, CPA, CFA, also known as Doug, is CFO & Principal Accounting Officer of Barinthus Biotherapeutics plc. since May 01, 2026. Mr. Swirsky served as Chief Financial Officer at MaxCyte, Inc. since March 28, 2023 until March 30, 2026. He joined MaxCyte, Inc. in March 28, 2023. He served as Chief Financial Officer and Treasurer at AavantiBio, Inc. since February 1, 2021 until December 2022. He served as AavantiBio Interim President and a director from May 2020 to October 2020. He served as an Independent Chairman of Board of NeuroBo Pharmaceuticals, Inc. since January 11, 2021 until January 14, 2022. He had been President of Rexahn Pharmaceuticals, Inc. since January 2, 2018 until November 2020 and served as its Chief Executive Officer and Director since November 14, 2018 until November 2020. He served as Independent Director at NeuroBo Pharmaceuticals, Inc. since September 01, 2020 until January 14, 2022. Mr. Swirsky served as Corporate Secretary and Chief Financial Officer of Rexahn Pharmaceuticals, Inc. January 2018 to November 2018. He served as the Chief Executive Officer and President of GenVec, Inc. since 2014 until June 16, 2017 and served as its Corporate Secretary since September 18, 2006 until June 16, 2017. He served as the Chief Financial Officer of GenVec, Inc. from September 18, 2006 to December 2014 and served as its Treasurer since September 18, 2006. He served as Principal Accounting Officer at GenVec, Inc. until December 2014and served as its Senior Vice President. He served as the Managing Director and the Head of Life Sciences Investment Banking of Stifel Nicolaus from 2005 to 2006 and Legg Mason from 2002 to 2005. He held investment-banking positions at UBS, PaineWebber and Morgan Stanley. His experience includes positions in public accounting and consulting. He has been Board Chairman of Cellectar Biosciences, Inc. since August 2017. He served as the President and Chief Executive Officer at Ocuphire Pharma, Inc. He served as the Chairman of the Board at Fibrocell Science, Inc. since December 19, 2016. He served as an Independent Director of PolyMedix, Inc. since June 30, 2009 until March 2013 and Fibrocell Science, Inc. since March 2013. He has been a Director at Cellectar Biosciences, Inc. since April 2017. Mr. Swirsky has been a Member of the Business Advisory Board at Calibrant Biosystems, Inc. since August 2008. He served as a Director of GenVec, Inc. since September 18, 2013 until June 16, 2017. Mr. Swirsky is a Certified Public Accountant and Chartered Financial Analyst. He has been recognized as NACD Directorship Certified™ by the National Association of Corporate Directors. Mr. Swirsky received his B.S. in Business in Administration in Accounting from Boston University in the year 1989 to 1992 and master’s in business administration from the Kellogg School of Management at Northwestern University in the year 1996 to 1997. He had been a Non-Executive Independent Director at Pernix Therapeutics Holdings, Inc. since November 15, 2017.

公司職務